Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Lauren M. Rosati

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6159-9780; OpenAlex author ID A5080190586. Sources: OpenAlex.

Their work

Papers
23 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
85
Papers, trials and grants by year

2014: 1 paper · 2015: 4 papers · 2016: 3 papers · 2017: 7 papers · 2018: 5 papers · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 23

  1. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and … Co-author DOI 10.1016/j.ijrobp.2024.10.039↗
  2. Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled… First author DOI 10.1016/j.prro.2022.02.009↗
  3. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderlin… First author DOI 10.1245/s10434-021-11202-8↗
  4. Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation thera… First author DOI 10.1016/j.adro.2018.07.002↗
  5. Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated Wit… Co-author DOI 10.1016/j.ijrobp.2017.10.001↗
  6. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conven… First author DOI 10.1016/j.surg.2017.11.027↗
  7. Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective. Co-author DOI 10.1245/s10434-017-6134-6↗
  8. Stereotactic body radiation therapy for palliative management of pancreatic adenocarcinoma in elderly and medically inoperable patients. First author DOI 10.18632/oncotarget.24713↗
  9. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Co-author DOI 10.1002/cam4.1104↗
  10. A Novel Absorbable Radiopaque Hydrogel Spacer to Separate the Head of the Pancreas and Duodenum in Radiation Therapy for Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2017.08.006↗
  11. Integration of Stereotactic Body Radiation Therapy into the Multidisciplinary Management of Pancreatic Cancer. Co-author DOI 10.1016/j.semradonc.2017.02.005↗
  12. An unusual genomic variant of pancreatic ductal adenocarcinoma with an indolent clinical course. First author DOI 10.1101/mcs.a001701↗
  13. Personalized Management of Pancreatic Ductal Adenocarcinoma Patients through Computational Modeling. Co-author DOI 10.1158/0008-5472.can-16-1208↗
  14. Role of Stereotactic Body Radiotherapy in the Treatment of Elderly and Poor Performance Status Patients With Pancreatic Cancer. Co-author DOI 10.1200/jop.2016.020628↗
  15. A rare case of esophageal metastasis from pancreatic ductal adenocarcinoma: a case report and literature review. Co-author DOI 10.18632/oncotarget.18458↗
  16. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2015.11.026↗
  17. Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cance… Co-author DOI 10.1016/j.prro.2016.05.005↗
  18. Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions. Co-author DOI 10.1586/14737140.2016.1168698↗
  19. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocar… Co-author DOI 10.1002/cncr.29161↗
  20. The role of radiation therapy in pancreatic ductal adenocarcinoma in the neoadjuvant and adjuvant settings. First author DOI 10.1053/j.seminoncol.2014.12.013↗
  21. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. Co-author DOI 10.1245/s10434-014-4274-5↗
  22. Advances of stereotactic body radiotherapy in pancreatic cancer. Co-author DOI 10.3978/j.issn.1000-9604.2015.04.12↗
  23. Stereotactic body radiation therapy in pancreatic cancer: the new frontier. Co-author DOI 10.1586/14737140.2014.952286↗

Closest collaborators

The 25 strongest of 85 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joseph M. Herman · 23 shared papers, 2014–2025 · strength 1.77
  2. Amy Hacker‐Prietz · 12 shared papers, 2015–2025 · strength 0.93
  3. Amol Kumar Narang · 10 shared papers, 2017–2025 · strength 0.88
  4. Daniel A. Laheru · 11 shared papers, 2015–2025 · strength 0.88
  5. Dung Thi Le · 9 shared papers, 2015–2025 · strength 0.81
  6. Lei Zheng · 10 shared papers, 2015–2022 · strength 0.71
  7. Matthew John Weiss · 9 shared papers, 2015–2022 · strength 0.66
  8. Timothy Michael Pawlik · 8 shared papers, 2015–2025 · strength 0.65
  9. Jin Peng He · 7 shared papers, 2017–2022 · strength 0.56
  10. Colin Hill · 3 shared papers, 2022–2025 · strength 0.46
  11. Christopher Lee Wolfgang · 7 shared papers, 2015–2022 · strength 0.44
  12. Ralph H. Hruban · 6 shared papers, 2017–2022 · strength 0.42
  13. Christopher L. Wolfgang · 4 shared papers, 2016–2025 · strength 0.37
  14. Elizabeth M. Jaffee · 4 shared papers, 2016–2025 · strength 0.37
  15. Ana De Jesus‐Acosta · 4 shared papers, 2015–2022 · strength 0.27
  16. Matthew John Weiss · 2 shared papers, 2018–2025 · strength 0.26
  17. Shuchi Sehgal · 2 shared papers, 2022 · strength 0.26
  18. Christine A. Iacobuzio–Donahue · 4 shared papers, 2015–2017 · strength 0.23
  19. Lei Zheng · 1 shared paper, 2025 · strength 0.20
  20. Eric R. Lutz · 1 shared paper, 2025 · strength 0.20
  21. Richard David Schulick · 1 shared paper, 2025 · strength 0.20
  22. Eun Ji Shin · 3 shared papers, 2017–2018 · strength 0.19
  23. Albert C. Koong · 4 shared papers, 2014–2018 · strength 0.19
  24. Daniel Tandel Chang · 4 shared papers, 2014–2018 · strength 0.19
  25. Rachit Kumar · 2 shared papers, 2015–2017 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.